Rachel Narozniak, MA


Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

December 15th 2020

TP53-mutant myelodysplastic syndromes and acute myeloid leukemia represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival.

The Therapeutic Toolkit for MDS-Associated Anemia Adds Luspatercept

December 2nd 2020

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

METex14+ NSCLC Armamentarium Welcomes First Targeted Therapy

November 19th 2020

The first biomarker-drive intervention for patients with non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation is now available in clinical practice.

French Study Sheds Light on COVID-19 Stress Among Patients With Cancer

November 13th 2020

Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.

Uncovering TP53 Mutations in MDS, AML Requires NGS

November 12th 2020

TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.

First Nonoperative Option Arrives for Low-Grade UTUC

November 11th 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

October 14th 2020

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

Immunomedics Acquisition Transfers Development of Sacituzumab Govitecan to Gilead Sciences

October 8th 2020

Gilead Sciences’ acquisition of Immunomedics, the manufacturer of sacituzumab govitecan-hziy, is expected to advance the development of the antibody-drug conjugate not only across additional types of breast cancer beyond triple-negative disease, but also in other solid tumors.

Emotional AEs Remain a Blindspot in Oncology Care

October 6th 2020

Patients with cancer continue to find their health care providers “more helpful” in managing physical adverse effects resulting from cancer therapy compared with emotional or mental health AEs.

XmAb18087 Shows Encouraging Preliminary Activity in NETs

October 3rd 2020

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Dual CDK4/6, MEK Blockade Demonstrates Synergy in PNET Models

October 2nd 2020

Combination CDK4/6 and MEK inhibition was “highly synergistic” in killing pancreatic neuroendocrine tumor cells in vitro and effectively suppressed PNET growth in mice.

NSCLC Treatment Portfolio Gains RET-Targeted Therapy

October 1st 2020

In an interview with OncologyLive®, Justin F. Gainor, MD, discusses the impact pralsetinib may have on the RET-altered NSCLC paradigm.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Today’s Molecular Profiling Efforts Will Define the New Decade of GI Cancer Management

September 26th 2020

Over the past decade in gastrointestinal cancer treatment, the acknowledgement that cancer is heterogeneous and likely polyclonal has prompted a shift from gene testing for some patients, to many patients.

COVIPACT Data Sheds Light on Post-Traumatic Stress Prevalence Among Patients, HCPs Amid COVID-19

September 25th 2020

The coronavirus disease 2019 pandemic has increased levels of perceived and post-traumatic stress among oncology providers and patients with cancer alike, which suggest a need for psychosocial support resources to promote emotional resilience and reduce the risk of post-traumatic stress in patients on active therapy.

Study Endorses Benefits of Population-Based BRCA Screening

September 24th 2020

Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.

Europe’s Largest Prospective Dataset Confirms Cancer’s Correlation With COVID-19 Mortality

September 23rd 2020

Cancer is independently associated with mortality in patients admitted to the hospital due to coronavirus disease 2019 (COVID-19) infection.

Pembrolizumab Prolongs PFS in Rare Sarcoma Subtypes

September 21st 2020

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

SOLAR-1 OS Data Suggests Benefit in HR+/HER2– PIK3CA-Mutant Breast Cancer Subgroups

September 19th 2020

Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.